




The relative strengths and weaknesses of Avanir Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avanir Pharmaceuticals INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 10% points. The greatest weakness of Avanir Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 128% points.

The company's Economic Capital Ratio, given in the ranking table, is 138%, being 105% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	71,844
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	34,792
Liabilities, Non-Current	1,393
Other Assets	2,643
Other Compr. Net Income	0
Other Expenses	71,453
Other Liabilities	21,422
Other Net Income	52
Other Revenues	75,366
Property and Equipment	1,593
Research and Development	49,506
Selling, General and Administrative Expense	29,935

Output Variable	Value in 1000 USD
Assets	76,079
Liabilities	57,607
Expenses	150,894
Revenues	75,366
Stockholders Equity	18,472
Net Income	-75,476
Comprehensive Net Income	-75,476
BaseVar	179,999
ECR before LimitedLiability	-53%
Economic Capital Ratio	138%